Results 191 to 200 of about 151,067 (292)

TRPM8 levels determine tumor vulnerability to channel agonists

open access: yesMolecular Oncology, EarlyView.
TRPM8 is a Ca2+ permissive channel. Regardless of the amount of its transcript, high levels of TRPM8 protein mark different tumors, including prostate, breast, colorectal, and lung carcinomas. Targeting TRPM8 with channel agonists stimulates inward calcium currents followed by emptying of cytosolic Ca2+ stores in cancer cells.
Alessandro Alaimo   +18 more
wiley   +1 more source

Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte   +10 more
wiley   +1 more source

A Comparison Between Malignant Breast Neoplasms Apoptosis and Benign Breast Neoplasms Under Influence of DNA Fragmentation [PDF]

open access: yesMultidisciplinary Cancer Investigation, 2017
Ali Akbar Abolfathi   +4 more
openaire   +1 more source

Adverse event profile of lomustine and temozolomide: a descriptive analysis from WHO-VigiAccess. [PDF]

open access: yesFront Pharmacol
Luo H   +7 more
europepmc   +1 more source

Comprehensive omics‐based classification system in adult patients with B‐cell acute lymphoblastic leukemia

open access: yesMolecular Oncology, EarlyView.
The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song   +11 more
wiley   +1 more source

Primary exploration of cell-free DNA in the plasma of patients with parathyroid neoplasms using next-generation sequencing. [PDF]

open access: yesCancer Cell Int
Zheng Q   +9 more
europepmc   +1 more source

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

open access: yesMolecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy